Department of Medicine-The Royal Melbourne Hospital, University of Melbourne, Parkville 3050, Australia.
Population Health and Immunity Division, The Walter and Eliza Hall Institute of Medical Research, Parkville 3052, Australia.
Int J Mol Sci. 2022 Jun 30;23(13):7307. doi: 10.3390/ijms23137307.
Less than 50 years since tau was first isolated from a porcine brain, its detection in femtolitre concentrations in biological fluids is revolutionizing the diagnosis of neurodegenerative diseases. This review highlights the molecular and technological advances that have catapulted tau from obscurity to the forefront of biomarker diagnostics. Comprehensive updates are provided describing the burgeoning clinical applications of tau as a biomarker of neurodegeneration. For the clinician, tau not only enhances diagnostic accuracy, but holds promise as a predictor of clinical progression, phenotype, and response to drug therapy. For patients living with neurodegenerative disorders, characterization of tau dysregulation could provide much-needed clarity to a notoriously murky diagnostic landscape.
自 tau 蛋白首次从猪脑中分离出来以来，还不到 50 年的时间，其在纳升级生物流体中的检测浓度正在彻底改变神经退行性疾病的诊断方式。这篇综述重点介绍了推动 tau 蛋白从默默无闻发展到生物标志物诊断前沿的分子和技术进步。本文提供了详尽的最新临床应用信息，描述了 tau 蛋白作为神经退行性变生物标志物的应用。对于临床医生来说，tau 不仅提高了诊断的准确性，而且有望预测疾病的进展、表型和对药物治疗的反应。对于患有神经退行性疾病的患者来说，tau 失调的特征可能为这一诊断困难的疾病领域提供急需的清晰认识。
